Division of Endocrinology - Hospital de Clínicas - University of Buenos Aires, Ciudad de Buenos Aires, Argentina.
Endocr Relat Cancer. 2019 Oct;26(10):R553-R566. doi: 10.1530/ERC-19-0213.
The stratification of patients with differentiated thyroid cancer based on their initial risk of recurrence, according to specific clinical, histopathological and perioperative data, is an important starting point for tailoring the follow-up during the first 1-2 years after initial therapy (surgery with or without radioiodine ablation). However, risk of recurrence re-stratification based on new clinical data that becomes available after considering the response to treatment (dynamic risk assessment) provides a more accurate prediction of the status at final follow-up and a more individualized approach. In this review, we summarized the available data regarding dynamic risk of recurrence and the suggested management of differentiated thyroid cancer patients according to the response to treatment. The use of this strategy is crucial to avoid overtreatment and intensive follow-up of the vast majority of patients who will have a very good prognosis and, on the other hand, focus therapeutic efforts on those patients who will have a worse prognosis. In the future, molecular biology analysis of the tumors and well-designed prospective studies will probably refine the risk of recurrence prediction.
根据特定的临床、组织病理学和围手术期数据,对分化型甲状腺癌患者进行初始复发风险分层,是制定初始治疗(手术联合或不联合放射性碘消融)后 1-2 年内随访计划的重要起点。然而,根据治疗反应(动态风险评估)获得的新临床数据进行复发风险再分层,可以更准确地预测最终随访时的状态,并提供更个体化的治疗方案。在这篇综述中,我们总结了有关复发动态风险的现有数据,并根据治疗反应建议了分化型甲状腺癌患者的管理方法。这种策略的使用对于避免过度治疗和对绝大多数预后良好的患者进行密集随访至关重要,同时也将治疗重点放在那些预后较差的患者身上。未来,肿瘤的分子生物学分析和精心设计的前瞻性研究可能会进一步完善复发风险预测。